Inference of upstream-mutation and metabolomic-signature causality identifies prognostic biomarkers and therapeutic targets in pancreatic cancer

Journal:

Nature Communications

Published:

2026-05-30

DOI:

10.1038/s41467-026-73871-x

Affiliations:

9

Authors:

15

Go to article

Institutions	Authors	Share
State Key Laboratory of Molecular Oncology, China	5.000000	0.33
Precogify, China	3.000000	0.20
Cancer Institute and Hospital, CAMS & PUMC, China	2.500000	0.17
State Key Laboratory of Complex Severe and Rare Diseases, China	2.000000	0.13
Southern University of Science and Technology (SUSTech), China	1.000000	0.07
Tongji Hospital (TJH), HUST, China	0.500000	0.03
Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, China	0.500000	0.03
Henan Cancer Hospital, ZZU, China	0.500000	0.03